Current progress and prospect of immune checkpoint inhibitors in hepatocellular carcinoma (Review)
- Authors:
- Zhu Zeng
- Biao Yang
- Zheng-Yin Liao
-
Affiliations: Department of Abdominal Oncology, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China, Department of Gastroenterology, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan 610041, P.R. China - Published online on: July 24, 2020 https://doi.org/10.3892/ol.2020.11909
- Article Number: 45
-
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
 |
|
McGlynn KA, Petrick JL and London WT: Global Epidemiology of Hepatocellular Carcinoma: An emphasis on demographic and regional variability. Clin Liver Dis. 19:223–238. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, Jemal A, Kramer JL and Siegel RL: Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 69:363–385. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng H, Chen W, Zheng R, Zhang S, Ji JS, Zou X, Xia C, Sun K, Yang Z, Li H, et al: Changing cancer survival in China during 2003–15: A pooled analysis of 17 population-based cancer registries. Lancet Glob Health. 6:e555–e567. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y and El-Serag HB: Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents. Gastroenterology. 153:996–1005.e1. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Tan AT, Yang N, Lee Krishnamoorthy T, Oei V, Chua A, Zhao X, Tan HS, Chia A, Le Bert N, Low D, et al: Use of expression profiles of HBV-DNA integrated into genomes of hepatocellular carcinoma cells to select T cells for immunotherapy. Gastroenterology. 156:1862–1876.e9. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Vogel A, Cervantes A, Chau I, Daniele B, Llovet JM, Meyer T, Nault JC, Neumann U, Ricke J, Sangro B, et al: Hepatocellular carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 30:871–873. 2019. View Article : Google Scholar | |
|
Benson AB III, D'Angelica MI, Abbott DE, Abrams TA, Alberts SR, Saenz DA, Are C, Brown DB, Chang DT, Covey AM, et al: NCCN guidelines insights: Hepatobiliary cancers, version 1.2017. J Natl Compr Canc Netw. 15:563–573. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Bruix J, Reig M and Sherman M: Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology. 150:835–853. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, et al: Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 69:1492–1501. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Cui J, Wang N, Zhao H, Jin H, Wang G, Niu C, Terunuma H, He H and Li W: Combination of radiofrequency ablation and sequential cellular immunotherapy improves progression-free survival for patients with hepatocellular carcinoma. Int J Cancer. 134:342–351. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Lencioni R, Llovet JM, Han G, Tak WY, Yang J, Guglielmi A, Paik SW, Reig M, Kim DY, Chau GY, et al: Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial. J Hepatol. 64:1090–1098. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Abou-Alfa GK, Meyer T, Cheng AL, El-Khoueiry AB, Rimassa L, Ryoo BY, Cicin I, Merle P, Chen Y, Park JW, et al: Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N Engl J Med. 379:54–63. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, et al: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 389:56–66. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, et al: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 359:378–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Greten TF, Lai CW, Li G and Staveley-O'Carroll KF: Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 156:510–524. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Maur M, Tomasello C, Frassoldati A, Dieci MV, Barbieri E and Conte P: Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol. 30:e76–e78. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Buchbinder EI and Desai A: CTLA-4 and PD-1 Pathways: Similarities, differences, and implications of their inhibition. Am J Clin Oncol. 39:98–106. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Sprinzl MF and Galle PR: Current progress in immunotherapy of hepatocellular carcinoma. J Hepatol. 66:482–484. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Prieto J, Melero I and Sangro B: Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 12:681–700. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Wang L and Wang FS: Clinical immunology and immunotherapy for hepatocellular carcinoma: Current progress and challenges. Hepatol Int. 13:521–533. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Kudo M: Immuno-oncology in hepatocellular carcinoma: 2017 Update. Oncology. 93 (Suppl 1):S147–S159. 2017. View Article : Google Scholar | |
|
Waidmann O: Recent developments with immunotherapy for hepatocellular carcinoma. Expert Opin Biol Ther. 18:905–910. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Johnston MP and Khakoo SI: Immunotherapy for hepatocellular carcinoma: Current and future. World J Gastroenterol. 25:2977–2989. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Tian M, Shi Y, Liu W and Fan J: Immunotherapy of hepatocellular carcinoma: Strategies for combinatorial intervention. Sci China Life Sci. 62:1138–1143. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Finn RS, Ryoo BY, Merle P, Kudo M, Bouattour M, Lim HY, Breder VV, Edeline J, Chao Y, Ogasawara S, et al: Results of KEYNOTE-240: Phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC). J Clin Oncol. 37 (15 Suppl):S40042019. View Article : Google Scholar | |
|
Eggert T and Greten TF: Tumor regulation of the tissue environment in the liver. Pharmacol Ther. 173:47–57. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Nishida N and Kudo M: Immunological microenvironment of hepatocellular carcinoma and its clinical implication. Oncology. 92 (Suppl 1):S40–S49. 2017. View Article : Google Scholar | |
|
Tiegs G and Lohse AW: Immune tolerance: What is unique about the liver. J Autoimmun. 34:1–6. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Huz JI, Melis M and Sarpel U: Spontaneous regression of hepatocellular carcinoma is most often associated with tumour hypoxia or a systemic inflammatory response. HPB (Oxford). 14:500–505. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Crispe IN: Liver antigen-presenting cells. J Hepatol. 54:357–365. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Jiang Y, Han QJ and Zhang J: Hepatocellular carcinoma: Mechanisms of progression and immunotherapy. World J Gastroenterol. 25:3151–3167. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Josefowicz SZ, Lu LF and Rudensky AY: Regulatory T cells: Mechanisms of differentiation and function. Annu Rev Immunol. 30:531–564. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Gong J, Chehrazi-Raffle A, Reddi S and Salgia R: Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. J Immunother Cancer. 6:82018. View Article : Google Scholar : PubMed/NCBI | |
|
Zou W, Wolchok JD and Chen L: PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Sci Transl Med. 8:328rv42016. View Article : Google Scholar : PubMed/NCBI | |
|
Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, et al: Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features. Hepatology. 64:2038–2046. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Wei F, Zhong S, Ma Z, Kong H, Medvec A, Ahmed R, Freeman GJ, Krogsgaard M and Riley JL: Strength of PD-1 signaling differentially affects T-cell effector functions. Proc Natl Acad Sci USA. 110:E2480–E2489. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
El Dika I, Khalil DN and Abou-Alfa GK: Immune checkpoint inhibitors for hepatocellular carcinoma. Cancer. 125:3312–3319. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Noonan A and Pawlik TM: Hepatocellular carcinoma: An update on investigational drugs in phase I and II clinical trials. Expert Opin Investig Drugs. 28:941–949. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Mizukoshi E and Kaneko S: Immune cell therapy for hepatocellular carcinoma. J Hematol Oncol. 12:522019. View Article : Google Scholar : PubMed/NCBI | |
|
Liang SC, Latchman YE, Buhlmann JE, Tomczak MF, Horwitz BH, Freeman GJ and Sharpe AH: Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur J Immunol. 33:2706–2716. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Bajorath J, Flies DB, Dong H, Honjo T and Chen L: Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med. 197:1083–1091. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Elhag OA, Hu XJ, Wen-Ying Z, Li X, Yuan YZ, Deng LF, Liu DL, Liu YL and Hui G: Reconstructed adeno-associated virus with the extracellular domain of murine PD-1 induces antitumor immunity. Asian Pac J Cancer Prev. 13:4031–4036. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Intlekofer AM and Thompson CB: At the bench: Preclinical rationale for CTLA-4 and PD-1 blockade as cancer immunotherapy. J Leukoc Biol. 94:25–39. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, Chen L, Pardoll DM, Topalian SL and Anders RA: Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 20:5064–5074. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Benson AB 3rd, D'Angelica MI, Abbott DE, et al: NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017. J Natl Compr Canc Netw. 15:563–573. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH Rd, et al: Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet. 389:2492–2502. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Yau T, Hsu C, Kim TY, Choo SP, Kang YK, Hou MM, Numata K, Yeo W, Chopra A, Ikeda M, et al: Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 71:543–552. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sangro B, Park JW, Cruz CMD, Anderson J, Lang L, Neely J, Shaw JW and Cheng AL: A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459. J Clin Oncol. 34 (15 Suppl):TPS41472016. View Article : Google Scholar | |
|
Exposito MJ, Akce M, Alvarez J, Assenat E, Balart L, Baron A, Decaens T, Heurgue-Berlot A, Martin A, Paik S, et al: Abstract No. 526 CheckMate-9DX: Phase 3, randomized, double-blind study of adjuvant nivolumab vs placebo for patients with hepatocellular carcinoma (hcc) at high risk of recurrence after curative resection or ablation. J Vasc Interv Radiology. 30:S227–S228. 2019. View Article : Google Scholar | |
|
Zhu AX, Finn RS, Edeline J, Cattan S, Ogasawara S, Palmer D, Verslype C, Zagonel V, Fartoux L, Vogel A, et al: Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial. Lancet Oncol. 19:940–952. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Finn RS, Chan SL, Zhu AX, Knox JJ, Cheng AL, Siegel AB, Bautista O and Kudo M: Phase 3, randomized study of pembrolizumab (pembro) vs best supportive care (BSC) for second-line advanced hepatocellular carcinoma (HCC): KEYNOTE-240. J Clin Oncol. 35 (15 Suppl):TPS41432017. View Article : Google Scholar | |
|
Qin SK, Ren ZG, Meng ZQ, Chen ZD, Chai XL, Xiong JP, Bai YX, Yang L, Zhu H, Fang WJ, et al: LBA27A randomized multicentered phase II study to evaluate SHR-1210 (PD-1 antibody) in subjects with advanced hepatocellular carcinoma (HCC) who failed or intolerable to prior systemic treatment. Ann Oncol. 29 (Suppl 8):mdy424.029. 2018. View Article : Google Scholar | |
|
Qin SK, Ren Z, Meng Z, Chen Z, Chai X, Xiong J, Bai Y, Yang L, Zhu H, Fang W, et al: Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol. 21:571–580. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Xu JM, Zhang Y, Jia R, Wang Y, Liu R, Zhang G, Zhao C, Zhang Y, Zou J and Wang Q: Anti-programmed death-1 antibody SHR-1210 (S) combined with apatinib (A) for advanced hepatocellular carcinoma (HCC), gastric cancer (GC) or esophagogastric junction (EGJ) cancer refractory to standard therapy: A phase 1 trial. J Clin Oncol. 36 (15 Suppl):S40752018. View Article : Google Scholar | |
|
Qin S, Chen Z, Liu Y, Xiong J, Ren Z, Meng Z, Gu S, Wang L, Zou J; Jinling Hospital, ; et al: A phase II study of anti-PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer. J Clin Oncol. 37 (15 Suppl):S40742019. View Article : Google Scholar | |
|
Pishvaian MJ, Lee M, Ryoo BY, Stein S, Lee KH, Stein W, Spahn J, Shao H, Liu B and Iizuka K: LBA26Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC). Ann Oncol. 29 (Suppl 8):viii718–viii719. 2018. View Article : Google Scholar | |
|
Cheng AL, Qin S, Ikeda M, Galle P, Ducreux M, Zhu A, Kim TY, Merle P, Kaseb A, Li D, et al: IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo)+ bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Ann Oncol. 30:ix186–ix187. 2019. View Article : Google Scholar | |
|
Qin SK, Ren ZG, Feng Y, et al: Efficacy and safety of atezolizumab + bevacizumab vs sorafenib in Chinese patients with unresectable HCC in the phase III IMbrave150 study. EASL Liver Cancer Summit 2020. OP02-03. Ann Oncol. 30:v8752020. | |
|
Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, et al: Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet. 391:1163–1173. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Ikeda M, Sung MW, Kudo M, Kobayashi M, Baron AD, Finn RS, Kaneko S, Kraljevic S, Ishikawa K, Siegel AB, et al: A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEM) in patients (pts) with unresectable hepatocellular carcinoma (uHCC). J Clin Oncol. 36 (15 Suppl):S40762018. View Article : Google Scholar | |
|
Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Kim HS, Kim SU and Park MS: Reproducibility of European Association for the Study of the liver criteria and modified response evaluation criteria in solid tumors in patients treated with sorafenib. Liver Int. 38:1655–1663. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet J, Shepard KV, Finn RS, Ikeda M, Sung M, Baron DA, Kudo M, Okusaka T, Kobayashi M, Kumada H, et al: A phase Ib trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): Updated results. Ann Oncol. 30:v286–v287. 2019. View Article : Google Scholar | |
|
Kudo M, Ikeda M, Motomura K, Okusaka T, Kato N, Dutcus CE, Hisai T, Suzuki M, Ikezawa H, Iwata T, et al: A phase 1b study of lenvatinib plus nivolumab in patients with unresectable hepatocellular carcinoma (Study 117). J Clin Oncol. 38 (4 Suppl):S5132020. View Article : Google Scholar | |
|
Agdashian D, ElGindi M, Xie C, Sandhu M, Pratt D, Kleiner DE, Figg WD, Rytlewski JA, Sanders C, Yusko EC, et al: The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma. Cancer Immunol Immunother. 68:599–608. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, et al: A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol. 59:81–88. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Yau T, Kang YK, Kim TY, El-Khoueiry AB, Santoro A, Sangro B, Melero I, Kudo M, Hou MM, Matilla A, et al: Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040. J Clin Oncol. 37 (15 Suppl):S40122019. View Article : Google Scholar | |
|
Finkelmeier F, Waidmann O and Trojan J: Nivolumab for the treatment of hepatocellular carcinoma. Expert Rev Anticancer Ther. 18:1169–1175. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Opdivo Prescribing Information. Opdivo U.S. Product Information. Last updated. March. 2020, Princeton, NJ: Bristol Myers Squibb Company; | |
|
Abou-Alfa GK, Chan SL, Furuse J, Galle PR, Kelley RK, Qin S, Armstrong J, Darilay A, Vlahovic G, Negro A and Sangro B: A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study. J Clin Oncol. 36 (15 Suppl):TPS41442018. View Article : Google Scholar | |
|
Kelley RK, Abou-Alfa GK, Bendell JC, Kim TY, Borad MJ, Yong WP, Morse M, Kang YK, Rebelatto M, Makowsky M, et al: Phase I/II study of durvalumab and tremelimumab in patients with unresectable hepatocellular carcinoma (HCC): Phase I safety and efficacy analyses. J Clin Oncol. 35 (15 Suppl):S40732017. View Article : Google Scholar | |
|
Choi C, Yoo GS, Cho WK and Park HC: Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma. World J Gastroenterol. 25:2416–2429. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hilmi M, Neuzillet C, Calderaro J, Lafdil F, Pawlotsky JM and Rousseau B: Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions. J Immunother Cancer. 7:3332019. View Article : Google Scholar : PubMed/NCBI | |
|
Xu W, Liu K, Chen M, Sun JY, McCaughan GW, Lu XJ and Ji J: Immunotherapy for hepatocellular carcinoma: Recent advances and future perspectives. Ther Adv Med Oncol. 11:17588359198626922019. View Article : Google Scholar : PubMed/NCBI | |
|
Loosen SH, Schulze-Hagen M, Bruners P, Tacke F, Trautwein C, Kuhl C, Luedde T and Roderburg C: Sarcopenia is a negative prognostic factor in patients undergoing transarterial chemoembolization (TACE) for hepatic malignancies. Cancers (Basel). 11:15032019. View Article : Google Scholar | |
|
Harding JJ, Erinjeri JP, Tan BR, Reiss KA, Mody K, Khalil D, Yarmohammadi H, Nadolski G, Giardina JD, Capanu M, et al: A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC). J Clin Oncol. 36 (15 Suppl):TPS41462018. View Article : Google Scholar | |
|
Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y, et al: PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 5:e11766532016. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Kang YK, Yen CJ, Finn RS, Galle PR, Llovet JM, Assenat E, Brandi G, Pracht M, Lim HY, et al: Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 20:282–296. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhu AX, Park JO, Ryoo BY, Yen CJ, Poon R, Pastorelli D, Blanc JF, Chung HC, Baron AD, Pfiffer TE, et al: Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 16:859–870. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Sideras K, Biermann K, Verheij J, Takkenberg BR, Mancham S, Hansen BE, Schutz HM, de Man RA, Sprengers D, Buschow SI, et al: PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma. Oncoimmunology. 6:e12733092017. View Article : Google Scholar : PubMed/NCBI | |
|
Li H, Wu K, Tao K, Chen L, Zheng Q, Lu X, Liu J, Shi L, Liu C, Wang G and Zou W: Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma. Hepatology. 56:1342–1351. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Eso Y, Shimizu T, Takeda H, Takai A and Marusawa H: Microsatellite instability and immune checkpoint inhibitors: Toward precision medicine against gastrointestinal and hepatobiliary cancers. J Gastroenterol. 55:15–26. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Latham A, Srinivasan P, Kemel Y, Shia J, Bandlamudi C, Mandelker D, Middha S, Hechtman J, Zehir A, Dubard-Gault M, et al: Microsatellite instability is associated with the presence of lynch syndrome pan-cancer. J Clin Oncol. 37:286–295. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Kawaoka T, Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Morio K, Fujino H, et al: Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab. Hepatol Res. 50:885–888. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Goumard C, Desbois-Mouthon C, Wendum D, Calmel C, Merabtene F, Scatton O and Praz F: Low levels of microsatellite instability at simple repeated sequences commonly occur in human hepatocellular carcinoma. Cancer Genomics Proteomics. 14:329–339. 2017.PubMed/NCBI | |
|
Ando Y, Yamauchi M, Suehiro Y, Yamaoka K, Kosaka Y, Fuji Y, Uchikawa S, Kodama K, Morio K, Fujino H, et al: Complete response to pembrolizumab in advanced hepatocellular carcinoma with microsatellite instability. Clin J Gastroenterol. Feb 4–2020.(Online ahead of print). View Article : Google Scholar | |
|
Scheiner B, Kirstein MM, Hucke F, Finkelmeier F, Schulze K, von Felden J, Koch S, Schwabl P, Hinrichs JB, Waneck F, et al: Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: Efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 49:1323–1333. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI | |
|
Boni C, Barili V, Acerbi G, Rossi M, Vecchi A, Laccabue D, Penna A, Missale G, Ferrari C and Fisicaro P: HBV immune-therapy: from molecular mechanisms to clinical applications. Int J Mol Sci. 20:27542019. View Article : Google Scholar | |
|
Gao L, Yang X, Yi C and Zhu H: Adverse events of concurrent immune checkpoint inhibitors and antiangiogenic agents: A systematic review. Front Pharmacol. 10:11732019. View Article : Google Scholar : PubMed/NCBI |
